Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five ...

The congenital hyperinsulinism market has demonstrated remarkable growth, attributed to increasing awareness, early diagnosis, and the rise of personalized treatments. Valued at USD 194.5 billion in ...

Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Congenital Hyperinsulinism Market" report has been added to ResearchAndMarkets.com's offering. The congenital hyperinsulinism market has demonstrated ...